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To address an important risk classification issue that arises in
clinical practice, we propose a new mixture model via latent cure rate
markers for survival data with a cure fraction. In the proposed model,
the latent cure rate markers are modeled via a multinomial logistic
regression and patients who share the same cure rate are classified
into the same risk group. Compared to available cure rate models,
the proposed model fits better to data from a prostate cancer clini-
cal trial. In addition, the proposed model can be used to determine
the number of risk groups and to develop a predictive classification
algorithm.
1. Introduction. In cure rate modeling of event-time data, a fraction of
the population is considered to have zero hazard. The model is often suit-
able for survival data from cancer clinical trials owing to advances in medical
treatment and health care. For example, treatment of prostate cancer rou-
tinely cures the patient in the sense of completely eradicating the disease.
Existing cure rate models are able to accommodate a fraction of the popula-
tion being cured [Berkson and Gage (1952) and Maller and Zhou (1996)] and
characteristics of tumor growth [Chen, Ibrahim and Sinha (1999), Tsodikov,
Ibrahim and Yakovlev (2003) and Cooner et al. (2007)]. However, risk-group
information is not easily incorporated. Prostate cancer patients can be classi-
fied into low, intermediate and high-risk groups on the basis of pre-treatment
characteristics, such as the level of prostate-specific antigen (PSA), biopsy
Gleason scores or clinical tumor categories [D’Amico et al. (1998, 2002)]. A
failure to incorporate risk stratification into the cure rate model can lead to
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poorly fitting statistical models and poorly estimated cure rates and predic-
tive probabilities of risk groups. We address this problem via a latent class
analysis of the cure rate model.
We consider data from a retrospective cohort study of n = 1235 men
treated with radical prostatectomy (RP) at Brigham and Women’s Hospi-
tal between 1988–2001, which is a subset of the data published in D’Amico
et al. (2002). The primary endpoint is the time to prostate-specific anti-
gen (PSA) recurrence or to the last follow-up, whichever came first. There
were 261 patients who had PSA recurrence after the radical prostatectomy.
We consider four prognostic factors: natural logarithm of prostate specific
antigen (LogPSA) prior to RP, biopsy Gleason score, the 1992 American
Joint Commission on Cancer (AJCC) clinical tumor category and the year
of radical prostatectomy (Year). D’Amico et al. (2002) considered three risk
groups based on PSA, biopsy Gleason score and clinical tumor category and
reported the estimates of 8-year PSA recurrence free survival for the three
risk groups based on the Kaplan–Mier (KM) method [Kaplan and Meier
(1958)]. For the subset of the data considered here, the KM estimates of
8-year PSA recurrence free survival are 88.7%, 57.4% and 23.4% for low-risk
patients (T1c, T2a, a PSA level ≤ 10 ng/mL), intermediate-risk patients
(T2b or Gleason score 7 or a PSA level > 10 and ≤ 20 ng/mL) and high-risk
patients (T2c or PSA level > 20 ng/mL or Gleason score ≥ 8), respectively.
This risk classification does capture that the low-risk patients have the high-
est PSA recurrence free survival and the high-risk patients have the lowest
PSA recurrence free survival. However, there are some limitations of this risk
classification. First, this risk classification is deterministic. In other words, it
is not associated with predictive probabilities of risk groups. Second, it may
be problematic, especially for those patients whose clinical characteristics
fall within the boundary between two risk groups. Third, this risk classifi-
cation is not flexible enough to incorporate other potentially important risk
factors. For example, the year of diagnosis or treatment may have a signifi-
cant effect on the “cure rate” and, thus, it may be an important factor for
risk classification. To overcome these limitations, we develop a predictive
classification algorithm based on the latent cure rate marker model. This al-
gorithm first computes the probabilities of risk groups for a patient based on
his clinical characteristics and then classifies him to a particular risk group
with the largest predictive probability. As shown in Table 4 in Section 5, for
a patient who had PSA of 5, and Gleason score ≤ 6, clinical stage T1 and
surgery in 2001, the predictive probabilities for three risk groups are 0.745,
0.241 and 0.014 and, thus, this patient will be classified into the “low risk”
group.
Overdiagnosis of clinically insignificant prostate cancer was considered a
major issue of prostate-specific antigen (PSA) screening since the U.S. Food
and Drug Administration approved PSA testing in 1986 as a way to monitor
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prostate cancer progression [Wang and Arnold (2002)]. Etzioni et al. (2002)
estimated rates of prostate cancer overdiagnosis due to PSA testing among
men who were 60 to 84 years old in 1988. Overdiagnosis may occur when
older men or men with comorbid illness who have very low risk disease are
treated. However, overdiagnosis is usually not the case for men treated with
surgery because they are healthy but they can have very low risk disease.
Since the data we analyze in this paper were from those men who went
to surgery, it may be appropriate to fit a cure rate model to this particular
prostate cancer data set. We include the year of RP in the analysis, as it may
have a significant effect on the “cure rate.” There are two reasons for this.
With time people are diagnosed after several PSA tests and serial screened
men are diagnosed earlier with more favorable disease [e.g., Martin et al.
(2008)] and with increased medical experience. Over time, the techniques of
treatment also improve, which can improve outcome due to a learning curve,
especially when new surgery (e.g., robotic RP) or radiation therapy (e.g.,
seed therapy) techniques are used. We fit both the Cox proportional hazards
regression model [Cox (1972)] and the proposed latent cure rate marker
model with a piecewise exponential baseline hazard function to this prostate
cancer data. We then computed the logarithm of pseudomarginal likelihood
(LPML) [Ibrahim, Chen and Sinha (2001), Chapter 6] and the Deviance
Information Criterion (DIC) proposed by Spiegelhalter et al. (2002) for each
model. From Table 2 in Section 5, we see that the best LPML and DIC
values are −821.5 and 1640.8 for the Cox model and −816.0 and 1613.7 for
the latent cure rate marker model. These results indicate that the cure rate
model fit the data much better than the noncure rate model. Thus, a cure
rate model is indeed needed for this data set.
Section 2 provides the detailed development of the proposed latent cure
rate model. The prior and posterior are discussed in Section 3. The pos-
terior predictive classification algorithm is developed in Section 4. Section
5 presents an analysis of the prostate cancer data. We conclude the paper
with brief discussions in Section 6.
2. The models.
2.1. Preliminary. Let yi denote the observed survival time and let νi
be the censoring indicator that equals 1 if yi is a failure time and 0 if it
is right censored for the ith subject. Also, let Ni denote the number of
metastatic-competent tumor cells and assume that the Ni’s are independent
Poisson random variables with mean θi. Suppose further that Wij denotes
the random time for the jth carcinogenic cell to produce a detectable can-
cer mass (incubation time for the jth carcinogenic cell) for the ith subject.
We assume that the variables Wij , i = 1,2, . . . , are independent and dis-
tributed with a common distribution function F (y), and are independent
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of Ni. The time to relapse of cancer can be defined by the random vari-
able Yi =min{Wij,0≤ j ≤Ni}, where P (Wi0 =∞) = 1. Then, the survival
function for the cure rate model for the ith subject is given by
Si(y) = P (Yi ≥ y) = exp{−θiF (y)}.(1)
Using (1), the cure rate is given by Si(∞) = exp(−θi), which is also equal
to P (Ni = 0). Other properties of the cure rate model (1) can be found in
Yakovlev et al. (1993), Yakovlev and Tsodikov (1996) and Chen, Ibrahim and
Sinha (1999). To build a regression model, Chen, Ibrahim and Sinha (1999)
introduced covariates through θi via θi ≡ θ(x
′
iβ) = exp(x
′
iβ), where xi =
(xi1, xi2, . . . , xip)
′ denotes the p× 1 vector of covariates for the ith subject
and β = (β1, β2, . . . , βp)
′ is the corresponding vector of regression coefficients,
i = 1,2, . . . , n. Let S(y) = 1− F (y) and f(y) = d
dy
F (y). Then the resulting
survival function is given by
Si(y|xi,β) = exp{− exp(x
′
iβ)F (y)}.(2)
We refer to (2) as the CIS model.
A natural extension of the CIS model is the cure rate double regression
model. Let β1 = (β11, β12, . . . , β1p)
′ and β2 = (β21, β22, . . . , β2p)
′. We assume
θi = exp(x
′
iβ1). A proportional hazards model is assumed for the distribution
function F (y) of the incubation time for noncured subjects. Specifically,
let the cumulative hazard function H(y) = exp(x′iβ2)H0(y), where H0(y) is
the baseline cumulative hazard function. Then, F (y) = 1− exp{−H(y)} =
1− exp{− exp(x′iβ2)H0(y)}. Under this assumption for F (y), we have
Si(y|xi,β) = exp(− exp(x
′
iβ1)[1− exp{− exp(x
′
iβ2)H0(y)}]),(3)
where β = (β′1,β
′
2)
′. Yakovlev and Tsodikov (1996) used parametric accel-
erated failure time effects on the cumulative hazards with a similar idea.
Model (3) in its semiparametric form has appeared in Broet et al. (2001),
where they tended to use a generalized Gompertz name for the model.
We see, from (3), that the model in (3) incorporates the covariates into
both the cure rate and the hazard function with double proportional haz-
ards structures. Thus, we refer to this model as the PHPH model. The
name “PHPH” was also introduced by Tsodikov (2002) for the semipara-
metric version of the model. Recently, Liu, Lu and Shao (2006) developed
the PHPH version of the standard cure rate model of Berkson and Gage
(1952).
Another extension of the CIS model is the latent activation cure rate
(LACR) model proposed by Cooner et al. (2007). Given Ni ≥ 1, let Wi(1) ≤
Wi(2) ≤ · · · ≤Wi(Ni) denote the ordered values of the Wij ’s. The time to
relapse of cancer is defined by Yi =Wi(Ri) for 1≤Ri ≤Ni and Wi0 if Ni =
0, where Ri is an integer valued variable. Cooner et al. (2007) specified
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a conditional distribution for Ri given Ni, denoted by [Ri|Ni]. When Ni
follows a Poisson distribution with mean θi = exp(xiβ) and [Ri|Ni] is a
discrete uniform on {1,2, . . . ,Ni} with probability
1
Ni
, the survival function
under the LACR model is given by
Si(y|xi,β) = exp{− exp(xiβ)}+ [1− exp{− exp(xiβ)}]S(y).(4)
Other distributions for Ni and [Ri|Ni] are also considered in Cooner et al.
(2007).
2.2. A new latent cure rate marker model. The latent cure rate marker
(LCRM) model assumes that the Ni’s are independent Poisson random vari-
ables with mean θgi , where gi is a (unknown) group indicator, and exp(−θgi)
is the cure rate marker. Let G denote the number of distinct values of θgi .
Further, gi (1 ≤ gi ≤ G) indicates the group membership. Without loss of
generality, we assume θ1 < θ2 < · · ·< θG. Under these constraints, the group
membership gi is uniquely defined. Similar to the PHPH model, we assume
the proportional hazards model for cumulative hazard function H(y), that
is, H(y) = exp(x′iβ)H0(y), where H0(y) is the baseline cumulative hazard
function. Then, under the LCRM model, the conditional survival function
of yi given θgi is of the form
Si(y|xi,β, θgi) = exp(−θgi [1− exp{− exp(x
′
iβ)H0(y)}]).(5)
We assume a multinomial logistic regression model for the latent group
membership gi. To this end, let z
′
i = (zi0, zi1, zi2, . . . , ziq) denote a (q+1)× 1
vector of covariates for the ith subject, which includes an intercept (i.e.,
zi0 = 1) for i = 1,2, . . . , n. Also let φj = (φj0, φj1, φj2, . . . , φjq)
′ denote the
corresponding vectors of regression coefficients for j = 1,2, . . . ,G and φ′ =
(φ′1,φ
′
2, . . . ,φ
′
G−1). Then the density of the group membership gi is given by
f(gi|zi,φ) =
exp(z′iφgi)∑G
l=1 exp(z
′
iφl)
.(6)
For notational convenience, we let φG = (0,0, . . . ,0)
′. Write θ′ = (θ1, θ2, . . . , θG).
Using (5), the unconditional survival function of yi is given by
Si(y|xi,zi,β,θ,φ)
(7)
=
G∑
k=1
exp(−θk[1− exp{− exp(x
′
iβ)H0(y)}])
exp(z′iφk)∑G
l=1 exp(z
′
iφl)
.
Unlike the CIS model, the LCRM model does not directly link the co-
variates to the cure fractions and instead it assumes that the population
is characterized by an unobserved cure rate marker, namely, exp(−θgi),
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where the latent group membership gi is described according to covari-
ates via a multinomial logistic regression model. We note that the mono-
tonic constraints on the cure rates θk’s not only define the group mem-
bership gi but also ensure identifiability of the multinomial logistic regres-
sion model. We also see, from (7), that the LCRM model is indeed a fi-
nite mixture of cure rate models. If θk → θ for k = 1,2, . . . ,G, (7) reduces
to
Si(y|xi,β, θ) = exp(−θ[1− exp{− exp(x
′
iβ)H0(y)}]),
which is a special case of the PHPH model.
We assume the piecewise exponential model for the baseline hazard func-
tion h0(y), which is constructed as follows. We first partition the time axis
into J intervals: (s0, s1], (s1, s2], . . . , (sJ−1, sJ ], where s0 = 0 < s1 < s2 <
· · · < sJ =∞. We then assume a constant hazard λj over the jth inter-
val Ij = (sj−1, sj]. That is, h0(y) = λj if y ∈ Ij for j = 1,2, . . . , J . Then the
corresponding cumulative distribution function (c.d.f.), F0(y|λ), is given by
F0(y|λ) = 1− exp
{
−λj(y− sj−1)−
j−1∑
g=1
λg(sg − sg−1)
}
(8)
for sj−1 ≤ y < sj , where λ= (λ1, . . . , λJ)
′. We note that when J = 1, F0(y|λ)
reduces to the parametric exponential model.
LetD= (n,y,X,Z,ν ,N,g) denote the complete data, where y= (y1, . . . , yn)
′,
ν = (ν1, ν2, . . . , νn)
′, X is the n× p matrix of covariates with ith row x′i, Z,
which may share common components with X , is a q-vector of covariates
with ith row z′i, N
′ = (N1,N2, . . . ,Nn), and g
′ = (g1, g2, . . . , gn). Then, the
complete data likelihood under the LCRM model is given by
L(β,θ,φ,λ|D)
=
n∏
i=1
[
J∏
j=1
(Niλj)
νiδij
× exp
{
νiδijx
′
iβ− exp(x
′
iβ)Niδij(9)
×
(
λj(yi − sj−1) +
j−1∑
k=1
λk(sk − sk−1)
)}]
× exp
[
n∑
i=1
{
Ni log θgi − log(Ni!)− θgi + z
′
iφgi − log
[
G∑
l=1
exp(z′iφl)
]}]
,
where δij = 1 if the ith subject failed or was censored in the jth interval
Ij , and 0 otherwise. Since N and g are not observed, by summing (9) over
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N and g, we obtain the likelihood function based on the observed data
Dobs = (n,y,X,Z,ν) given by
L(β,θ,φ,λ|Dobs)
=
n∏
i=1
G∑
k=1
(
exp
[
νi
{
log θk + x
′
iβ+
J∑
j=1
δij logλj − exp(x
′
iβ)H
∗
0 (yi)
}
(10)
− θk(1− exp{− exp(x
′
iβ)H
∗
0 (yi)})
]
× exp
{
z′iφk − log
(
G∑
l=1
exp(z′iφl)
)})
,
where H∗0 (yi) =
∑J
j=1 δij [λj(yi − sj−1) +
∑j−1
l=1 λl(sl − sl−1)].
3. The prior and posterior distributions under the LCRM model. We
consider a joint prior distribution for (β,θ,φ,λ). Suppose that J and sj ,
j = 1, . . . , J , are fixed. First we consider a fixed G. We assume that β, θ,
φ and λ are independent a priori. Thus, the joint prior for (β,θ,φ,λ) is of
the form π(β,θ,φ,λ) = π(β)π(θ)π(φ)π(λ). We further assume that
β ∼Np(0, c01Ip), φk ∼Nq(0, c02Iq), k = 1,2, . . . ,G− 1,(11)
π(λ)∝
J∏
j=1
λa0−1j exp(−b0λj),(12)
and
π(θ)∝
G∏
k=1
θak−1k exp(−bkθk), 0< θ1 < θ2 < · · ·< θG,(13)
where c01, c02, a0, b0, ak and bk, k = 1,2, . . . ,G, are the prespecified hy-
perparameters. Due to the monotonic constraints, θ1 < θ2 < · · · < θG, elic-
iting the hyper-parameters ak and bk becomes more crucial than other hy-
perparameters. To this end, we first specify θ0 = (θ01, θ02, . . . , θ0G)
′ such
that θ01 < θ02 < · · ·< θ0G. Equivalently, we specify a set of prior cure rates
exp(−θ0k), k = 1,2, . . . ,G. Then, we set ak =
1
c20
and bk =
1
c20θ0k
, where c0 is a
known constant. This essentially implies that we specify the prior mean and
the prior standard deviation of θk to be θ0k and c0θ0k. Thus, c0 quantifies
the prior uncertainty in θ0k. A large value of c0 reflects a vague prior belief
in θ0k and a small value of c0 yields a strong prior belief in θ0k. In Section
5 we use the LPML and DIC measures to guide the choice of c0 and θ0 and
we then conduct a sensitivity analysis on various choices of c0 and θ0.
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Based on the prior distributions specified above, the joint posterior dis-
tribution of β, θ, φ, λ, N and g based on the complete data D is thus given
by
π(β,θ,φ,λ,N,g|Dobs )∝ L(β,θ,φ,λ|D)π(β)π(θ)π(φ)π(λ),(14)
where L(β,θ,φ,λ|D) is defined in (9). We note that when the priors π(β),
π(θ), π(φ) and π(λ) are proper, the resulting posterior is proper. However,
even when we take an improper prior for θ, an improper uniform prior for β
and an improper Jeffreys-type prior for λ, that is, c01→∞ and a0 = b0 = 0
in (12), the posterior is still proper under some mild conditions. We formally
state this result in the following theorem.
Theorem 1. Suppose that π(β) ∝ 1 and π(λ) ∝
∏J
j=1λ
−1
j . Let Xj be
an n × (p + 1) matrix with its ith row equal to νiδij(1, x
′
i), where p is the
dimension of β. Assume that (i) when νi = 1, yi > 0, (ii) dj ≡
∑n
i=1 νiδij ≥ 1
for j = 1, . . . , J , (iii) there exists a j∗ such that Xj∗ is of full rank, and (iv)
c02 > 0, ak > 0 and bk ≥ 0 for k = 1,2, . . . ,G−1, d+
∑G−1
k=1 ak+aG > 0, where
d=
∑J
j=1 dj , and bG > 0. Then, the resulting posterior in (14) is proper.
The proof of the theorem is given in the Appendix. The conditions (i)–
(iii) are indeed quite mild and essentially require that all event times are
strictly positive, at least one event occurs in each chosen interval (sj−1, sj],
and the covariate matrix is of full rank for at least one interval. These con-
ditions are easily satisfied in most applications and are quite easy-to-check.
We note that the condition (iv) does not require aG > 0. Thus, π(θ) can
be improper. We also note that the latent structure of the LCRM model
leads to the development of a Markov chain Monte Carlo (MCMC) al-
gorithm for sampling from posterior distribution in (14). When G is not
specified, we assume a truncated Poisson distribution with mean µG on
{1,2, . . . ,Gmax} for G, where µG and Gmax are prespecified. Then, we de-
velop a reversible jump algorithm for carrying out posterior computation.
The description of the MCMC algorithm for a fixed G and the detailed de-
velopment of the reversible jump MCMC based on Lopes and West (2004)
and Green (1995) are given in online supplementary material [Kim, Xi and
Chen (2009)].
4. Posterior predictive classification under the LCRM model. In this
section we consider classification via the posterior predictive probability.
The latent cure rate markers under the LCRM model can be naturally used
for the predictive classification. Let xnew and znew denote the future values
of the vectors of baseline covariates. Also let gnew denote the future group
indicator. Suppose that gnew takes a value between 1 and G, where G is
LATENT CURE RATE MARKER MODEL 9
fixed. Then, the conditional posterior probability for gnew given φ and znew
is given by
P (gnew = k|φ,znew ,G) =
exp(z′newφk)∑G
l=1 exp(z
′
newφl)
, k = 1,2, . . . ,G.(15)
The posterior estimate of this predictive probability for gnew is the posterior
expectation of P (gnew = k|φ,znew ) given by
pˆ(k|znew ,G) =E[P (gnew = k|φ,znew ,G)|Dobs ](16)
for k = 1,2, . . . ,G, where the expectation is taken with respect to the pos-
terior distribution of φ based on the observed data Dobs . The clinical inter-
pretation of (16) is that, given the patient’s characteristic znew , pˆ(k|znew ) is
the probability that the patient is in the kth risk group.
Next, we consider the conditional predictive probability for gnew = k given
the survival time Y ≥ t, xnew and znew . This conditional predictive proba-
bility can be calculated as follows:
P (gnew = k|β,θ,φ,λ, t,xnew ,znew ,G)
(17)
=
exp(z′newφk − θk[1− exp{− exp(x
′
newβ)H
∗
0 (t)}])∑G
l=1 exp(z
′
newφl − θl[1− exp{− exp(x
′
newβ)H
∗
0 (t)}])
,
where H∗0 (t) is given in (10). The posterior estimate of (17) for gnew is
pˆ(k|t,xnew ,znew ,G) =E[P (gnew = k|β,θ,φ,λ, t,xnew ,znew )|Dobs ].(18)
From (16) and (18), it is easy to see that
pˆ(k|znew ,G) = pˆ(k|t= 0,xnew ,znew ,G)
for k = 1,2, . . . ,G. Since limt→∞H
∗
0 (t) =∞, we also have
lim
t→∞
pˆ(k|t,xnew ,znew ,G) =E
[
exp(z′newφk − θk)∑G
l=1 exp(z
′
newφl − θl)
]
,
(19)
k = 1,2, . . . ,G.
Using the posterior predictive probability in (18), we classify a new patient
with characteristic (xnew ,znew ) into risk group k
∗ if
k∗ = argmax
1≤k≤G
pˆ(k|t,xnew ,znew ,G).(20)
An attractive property of the posterior predictive probability in (18) is
presented in the following theorem.
Theorem 2. The posterior predictive probability for the lowest risk group
(k = 1), pˆ(1|t,xnew , znew ,G), increases in t, while for the highest risk group
(k =G), pˆ(G|t,xnew , znew ,G) decreases in t.
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The proof of Theorem 2 is given in the Appendix. Based on (19) and
Theorem 2, we have that, for t≥ 0,
Pˆ (gnew = 1|t,xnew ,znew ,G)≤E
[
exp(z′newφ1 − θ1)∑G
k=1 exp(z
′
newφk − θk)
]
,(21)
which is the largest probability that Pˆ (gnew = 1|t,xnew ,znew ,G) may achieve
for t > 0 given the patient’s characteristic (xnew ,znew ). Similarly, we have
Pˆ (gnew =G|t,xnew ,znew ,G)≥E
[
exp(z′newφG − θG)∑G
k=1 exp(z
′
newφk − θk)
]
,(22)
which is the smallest probability that Pˆ (gnew =G|t,xnew ,znew ,G) can get
for t > 0. The quantity Pˆ (gnew = k|t,xnew ,znew ,G) is clinically important
as this gives the patient an idea how well he can do prospectively given his
baseline characteristic.
Finally, we note that when G is not specified, a similar posterior predic-
tive classification algorithm can be established. For example, instead of (15),
we compute
P (gnew = k|φ,znew ) =
Gmax∑
G=1
π(G)
exp(z′newφk)∑G
l=1 exp(z
′
newφl)
, k = 1,2, . . . ,Gmax,
where π(G) denotes the prior distribution for G and Gmax is the largest
value of G.
5. Analysis of the prostate cancer data. We revisit the prostate cancer
data discussed in Section 1. The response variable y is the time to prostate-
specific antigen (PSA) recurrence. Covariates x1, x2, x3, x4 and x5 corre-
spond to LogPSA, biopsy Gleason score, clinical tumor category and the
year of radical prostatectomy (Year). A summary of covariates is given in
Table 1. The covariates LogPSA (x1) and Year (x5) are continuous, while
x2, x3 and x4 are binary. The mean and the standard deviation for LogPSA
were 1.95 and 0.72. We also set zj = xj for j = 1, . . . ,5. In all computations
we standardized all covariates by subtracting their respective sample means
and then being divided by their respective sample standard deviations.
The hyper-parameters of the prior distribution in Section 4 are specified as
follows. In (11), (12) and (13), we take c01 = 1000, c02 = 3, a0 = 1, b0 = 0.01
and c0 = 2.5. We choose c01 to be much larger than c02 as the posterior
is proper even when π(β) ∝ 1 according to Theorem 1. Also, a0 = 1 and
b0 = 0.01 are specified so that the prior for λ is relatively noninformative.
We further specify θ01 = − log(0.5) for G = 1; θ01 = − log(0.9) and θ02 =
− log(0.3) for G = 2; θ01 = − log(0.9), θ02 = − log(0.5) and θ03 =− log(0.1)
for G = 3; θ01 = − log(0.9), θ02 = − log(0.6), θ03 = − log(0.3) and θ04 =
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− log(0.1) for G= 4; and θ01 =− log(0.9), θ02 =− log(0.7), θ03 =− log(0.5),
θ04 = − log(0.3) and θ05 = − log(0.1) for G= 5. We note that (0.9,0.5,0.1)
for G= 3 were determined by the KM estimates of cure rates based on the
three risk groups defined in D’Amico et al. (1998, 2002).
Table 2 shows the values of LPML and DIC for the Cox, CIS, PHPH,
LACR and LCRM models for various J ’s and G’s. We note that under the
Cox model, the survival function is given by Si(y|xi,β,λ) =
exp{− exp(x′iβ)H0(y|λ)}, where H0(y|λ) is the cumulative baseline hazard
function corresponding to F0(y|λ) given in (8). From Table 2, we observe
that there is a concave pattern in the LPMLs and there is a convex pattern
in the DICs as functions of J for the CIS, PHPH and LCRM with fixed G.
We note that for J = 15, the values of LPML and DIC are −827.9 and 1648.9
for the Cox model and −838.0 and 1673.5 for the LACR model. Thus, the
concave (convex) pattern in the LPMLs (DICs) as functions of J still holds
for the Cox and LCRM models. Similar patterns are also observed in the
LPMLs and DICs as functions of G for fixed J under the LCRM. Among
the three J ’s shown in Table 2, J = 5 consistently fits the data better for
the CIS, PHPH and LCRM models and J = 10 fits the data better for the
Cox and LACR models. The LCRM model, with J = 5 and G= 3 fits the
data best among all models considered. In particular, LPML = −816.0 and
DIC = 1613.7 for the best LCRM model while LPML = −821.5 and DIC
= 1640.8 for the best Cox model. Except for G= 1, the LCRM model with
G≥ 2 improves the fit compared to the CIS, PHPH and LACR models.
The posterior estimates of the parameters under the best LCRM model
with J = 5 and G = 3 are given in Table 3. We see from this table that
LogPSA is significant in the proportional hazards model (5) for the survival
function for a “noncured” subject and LogPSA, G8H and Year of RP are
significant in the multinomial model (6) for the latent group membership
at a significance level of 0.05. In addition, Year of RP is nearly significant
in both models. Although the prior cure rates for the three risk groups are
0.9, 0.5 and 0.1, respectively, the resulting posterior estimates of these cure
Table 1
Summary of covariates for prostate cancer data
Covariate Coded variable Value Definition Frequency
x1 LogPSA (−∞,∞) Logarithm of PSA prior to RP –
(x2, x3) (G7, G8H) (0,0) Gleason score 6 or less 866
(1,0) Gleason score 7 303
(0,1) Gleason score 8–10 66
x4 Cstage 0 (T1) Clinical tumor category T1c or T2a 1055
1 (T2) Clinical tumor category T2b or T2c 180
x5 Year >0 Year of RP –
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Table 2
LPMLs and DICs of Cox, CIS, PHPH, LACR and LCRM models
J = 1 J = 5 J = 10
Model G LPML DIC LPML DIC LPML DIC
Cox −864.0 1722.3 −822.3 1642.4 −821.5 1640.8
CIS −827.4 1651.6 −821.6 1641.5 −822.4 1643.0
PHPH −831.5 1655.5 −824.2 1642.3 −825.4 1646.9
LACR −841.2 1680.6 −832.2 1662.6 −831.8 1661.6
LCRM 1 −845.8 1686.5 −821.3 1640.6 −823.3 1645.4
2 −823.3 1633.5 −820.8 1628.1 −822.6 1632.3
3 −822.9 1626.3 −816.0 1613.7 −819.5 1624.6
4 −823.9 1628.4 −817.1 1617.3 −820.3 1627.4
5 −824.4 1629.1 −818.0 1620.8 −821.7 1634.9
Table 3
Posterior estimates based on the best LCRM model
Posterior Posterior 95% HPD
Variable mean SD interval
β1 (LogPSA) 0.349 0.107 (0.136, 0.554)
β2 (G7) 0.117 0.135 (−0.141, 0.395)
β3 (G8H) 0.090 0.085 (−0.071, 0.260)
β4 (Cstage) 0.042 0.095 (−0.138, 0.231)
β5 (Year) −0.269 0.143 (−0.541, 0.016)
θ1 0.069 0.118 (0.000, 0.301)
θ2 1.193 0.582 (0.328, 2.316)
θ3 2.671 1.035 (1.443, 4.490)
exp(−θ1) 0.939 0.095 (0.740, 1.000)
exp(−θ2) 0.347 0.156 (0.059, 0.625)
exp(−θ3) 0.092 0.052 (0.000, 0.181)
φ10 (Intercept) 0.842 0.822 (−0.907, 2.431)
φ11 (LogPSA) −1.841 0.549 (−2.962, −0.963)
φ12 (G7) −1.162 0.924 (−3.349, 0.183)
φ13 (G8H) −1.801 1.068 (−4.128, −0.030)
φ14 (Cstage) −0.694 0.554 (−1.818, 0.181)
φ15 (Year) 0.840 0.373 (0.106, 1.597)
φ20 (Intercept) −0.385 1.152 (−2.670, 1.827)
φ21 (LogPSA) −3.123 0.987 (−5.160, −1.127)
φ22 (G7) 1.118 1.058 (−0.991, 3.163)
φ23 (G8H) −0.178 1.662 (−3.479, 2.878)
φ24 (Cstage) −0.741 1.266 (−3.224, 1.628)
φ25 (Year) 1.144 0.851 (−0.519, 2.884)
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rates are 0.939, 0.347 and 0.092. Under the same model setting for Table
3, the posterior predictive probabilities, pˆ(k|t,xnew ,znew ,G) given in (19)
with znew = xnew , are computed for three sets of baseline covariates xnew ’s
for various t’s and the results are given in Table 4. Based on the proposed
classification criterion given in (20), these probabilities clearly indicate that
a patient with a PSA level of 5, Gleason 6 or less, and tumor stage T1
belongs to risk group 1 (low risk group) and a patient with a PSA level of
30, Gleason 8 to 10, and tumor stage T2 falls into risk group 3 (high risk
group) no matter whether he had surgery in 1988 or 2001. However, a patient
with a PSA level of 5, Gleason 7 and tumor stage T2 may be classified into
risk group 3 (high risk group) if he had surgery in 1988 while a patient with
the same PSA level, Gleason score and tumor stage will be classified into
risk group 2 (intermediate risk group) if he had surgery in 2001. From Table
4, we also see that for each set of baseline covariates, the risk classification
does not change no matter how long the patient will live if he had surgery
in 2001 and this is not the case when he had surgery in 1988. In addition,
the overall cure rates,
S(∞|xnew ,znew ,β,θ,φ) =
G∑
k=1
exp(−θk)
exp(z′newφk)∑G
l=1 exp(z
′
newφl)
,
are presented in Table 4. It is interesting to see that when (PSA, Gleason,
Cstage) = (5, ≤6, T1), the overall cure rate is much smaller than that given
gnew = 1, when (PSA, Gleason, Cstage) = (5, 7, T2), the overall cure rate is
greater than that given gnew = 2 if he had surgery in 2001, while the over-
all cure rate is very similar to the risk group specific cure rate (gnew = 3)
when (PSA, Gleason, Cstage) = (30, 8–10, T2). Figure 1 shows the esti-
mated risk group specific PSA recurrence free probabilities corresponding
to these three sets of covariates and the estimated overall PSA recurrence
free probability when the year of RP was 2001. From plots (a), (b) and (c),
we see that three risk group specific probability curves are well separated
from each other. These plots also show that a wrong classification may lead
to either over-estimate or under-estimate of the PSA recurrence free prob-
ability. Thus, the posterior predictive classification is quite important, as a
correct classification leads to more accurate estimates of the cure rate as
well as the PSA recurrence free probability.
We further conducted a sensitivity analysis on the choice of c0 and θ0j ’s.
Table 5 shows the LPML and DIC values of the LCRM model with G= 3
for various c0 and the prior cure rates exp(θ0) = (0.9,0.5,0.1), (0.8, 0.5, 0.2)
and (0.7, 0.5, 0.3). Both LPML and DIC values are very similar for almost
all choices of c0. Among all values of c0 and exp(θ0), c0 = 2.5 and exp(θ0) =
(0.9,0.5,0.1) yield the largest LPML and the smallest DIC among all choices
considered. Although not reported in Table 5, the posterior estimates of
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Table 4
Posterior predictive probability based on the best LCRM model
Year PSA Gleason Stage t pˆ(k = 1|t) pˆ(k = 2|t) pˆ(k = 3|t) Overall cure rate
1988 5 ≤6 T1 0 0.692 0.099 0.209 0.705
5 0.814 0.085 0.101
∞ 0.910 0.061 0.029
5 7 T2 0 0.057 0.384 0.559 0.234
5 0.132 0.412 0.456
∞ 0.238 0.426 0.336
30 8–10 T2 0 0.001 0.053 0.947 0.098
5 0.005 0.068 0.928
∞ 0.008 0.072 0.920
2001 5 ≤6 T1 0 0.745 0.241 0.014 0.781
5 0.770 0.220 0.010
∞ 0.868 0.130 0.002
5 7 T2 0 0.183 0.657 0.160 0.409
5 0.220 0.653 0.127
∞ 0.327 0.618 0.055
30 8–10 T2 0 0.006 0.143 0.851 0.117
5 0.020 0.166 0.815
∞ 0.042 0.186 0.772
the cure rates were also calculated under those choices of c0 and the prior
cure rates. For example, when c0 = 2.5, the posterior estimates of the cure
rates and the corresponding posterior standard deviations are (0.939, 0.347,
0.092) and (0.095, 0.156, 0.052) for exp(θ0) = (0.9,0.5,0.1), (0.936, 0.351,
0.091) and (0.097, 0.161, 0.051) for exp(θ0) = (0.8,0.5,0.2), and (0.936,
0.352, 0.094) and (0.087, 0.163, 0.051) for exp(θ0) = (0.7,0.5,0.3). Similar
results are obtained for other choices of c0. These results demonstrate that
the proposed LCRM model is quite robust to the specification of c0 and
prior cure rates.
When G is not specified, we used the RJMCMC algorithm given in Kim,
Xi and Chen (2009). In the RJMCMC algorithm, we took a= 3 for θl and
dl = 0.5 for φl, l = 1,2, . . . ,G − 1. We specified the transition matrix as
follows:
TR=


0.0 1.0 0.0 0.0 0.0
0.5 0.0 0.5 0.0 0.0
0.0 0.5 0.0 0.5 0.0
0.0 0.0 0.5 0.0 0.5
0.0 0.0 0.0 1.0 0.0

 .
The dimension of model, G, is assumed to follow a Poisson distribution
with mean µG = 3 and truncated between 1 and 5. Also J is fixed to
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Fig. 1. Plots of the estimated risk group specific PSA recurrence free probabilities cor-
responding to (PSA, Gleason, Cstage) = (5, ≤6, T1) (a), (5, 7, T2) (b), and (30, 8–10,
T2) (c), and the estimated overall PSA recurrence free probability (d) for year of RP =
2001.
be 5. Under the above setting, the posterior probabilities of G are com-
puted and these are P (G= 1|Dobs ) = 0.0, P (G = 2|Dobs ) = 0.224, P (G =
3|Dobs ) = 0.534, P (G = 4|Dobs ) = 0.242, and P (G = 5|Dobs) = 0.0, respec-
tively. Therefore, the model with G = 3 has the highest posterior model
probability. This result is consistent with the best model identified by the
LPML and DIC measures shown in Table 2. We also conducted a sensi-
tivity analysis on the specification of µG in the prior distribution for G.
Specifically, we obtained that P (G= 1|Dobs ) = 0.0, P (G= 2|Dobs ) = 0.251,
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Table 5
LPMLs and DICs of the LCRM model for various c0 and prior cure rates
Prior cure rates
(0.9, 0.5, 0.1) (0.8, 0.5, 0.2) (0.7, 0.5, 0.3)
c0 LPML DIC LPML DIC LPML DIC
0.5 −816.9 1615.4 −817.7 1616.5 −817.8 1617.2
1.0 −816.6 1614.9 −817.2 1616.0 −817.2 1616.6
1.5 −816.4 1614.3 −816.7 1615.3 −816.7 1616.0
2.0 −816.2 1614.1 −816.4 1615.0 −816.6 1615.5
2.5 −815.9 1613.7 −816.2 1614.6 −816.3 1615.1
3.0 −816.1 1614.0 −816.2 1614.8 −816.4 1615.4
3.5 −816.1 1614.4 −816.3 1615.1 −816.6 1615.8
4.0 −816.4 1614.8 −816.4 1615.5 −817.0 1616.1
10.0 −816.6 1615.4 −816.9 1615.9 −817.3 1616.5
P (G= 3|Dobs ) = 0.535, P (G= 4|Dobs ) = 0.214, and P (G= 5|Dobs) = 0.0 for
µG = 2, and P (G= 1|Dobs) = 0.0, P (G= 2|Dobs) = 0.162, P (G= 3|Dobs) =
0.536, P (G = 4|Dobs ) = 0.302, and P (G = 5|Dobs ) = 0.0 for µG = 4. Thus,
the model with G = 3 consistently has the highest posterior model proba-
bility for all three choices of µG.
In all the computations, we first generated 100,000 Gibbs samples with a
burn-in of 4000 iterations, and we then used 20,000 iterations obtained from
every 5th iteration for computing all posterior estimates, including posterior
mean, posterior standard deviation, 95% highest posterior density (HPD)
intervals and LPML. The computer codes were written in FORTRAN 95
using IMSL subroutines with double precision accuracy. The convergence of
the MCMC sampling algorithm was checked using several diagnostic proce-
dures as recommended by Cowles and Carlin (1996).
6. Discussions. In Section 5 we used LPML and DIC measures to assess
the goodness of fit of the models for different choices of G and J . LPML is
a well-established Bayesian model comparison criterion based on the con-
ditional predictive ordinate (CPO) statistics, which is particularly suitable
for the cure rate models. Let CPOi denote the CPO statistic for the ith
subject. LPML is defined as
LPML=
n∑
i=1
log(CPOi).
The larger the LPML, the better the fit of a given model. Letting γ denote
the vector of all model parameters and L(γ|Dobs) the likelihood based on
the observed data Dobs , the DIC is defined as
DIC=Dev(γ¯) + 2pD,
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where Dev(γ) = −2 logL(γ|Dobs) is a deviance function, γ¯ is the poste-
rior mean of γ, pm =Dev(γ)−Dev(γ¯), and Dev(γ) is the posterior mean of
Dev(γ). For the LCRM model, γ = (β,θ,φ,λ) and L(γ|Dobs ) =
L(β,θ,φ,λ|Dobs), which is given by (10). The DIC is a Bayesian measure
of predictive model performance, which is decomposed into a measure of fit
and a measure of model complexity (pD). The smaller the value of DIC, the
better the model will predict new observations generated in the same way as
the data. As discussed in Spiegelhalter et al. (2002), DIC is the Bayesian ver-
sion of the Akaike Information Criterion (AIC) [Akaike (1973)]. Unlike AIC,
the dimensional penalty in DIC is automatically calculated without actu-
ally counting the number of parameters. Although the dimensional penalty
is not explicitly shown in LPML, LPML has a dimensional penalty similar
to AIC as derived by Gelfand and Dey (1994) based on the asymptotic ap-
proximation. Moreover, as discussed in Ibrahim, Chen and Sinha (2001), the
LPML measure is particularly suitable for comparing cure rate models, as
the moments do not exist under these models.
As discussed in Sections 1 and 2, there are several cure rate models for
survival data with a cure fraction recently developed in the literature. There
is a distinct difference between the proposed model and the existing ones.
Specifically, the new model is to no longer explain the cure fractions directly
according to covariates but to divide the population into latent classes char-
acterized by specific cure rates and being described according to covariates.
This nice feature of the proposed model allows us to develop the predictive
classification algorithm for classifying patients into different risk groups. The
proposed mixture model falls within the latent class modeling framework.
The latent class models are commonly used for analyzing complex sample
survey data. For survey data, a latent class model is often used to explain
unobservable categorical relationships or latent structures that characterize
discrete multivariate data [Dayton (1999), Agresti (2002) and Patterson,
Dayton and Graubard (2002)]. Recently, latent class models have been de-
veloped for survival data. Lin et al. (2002) proposed latent class models
for joint longitudinal and survival data. They assumed a Cox proportional
hazards model with time-varying covariates for the survival endpoint and
each latent class represents certain pattern of longitudinal and event-time
responses. Larsen (2004) extended the Cox model to encompass a latent class
variable (an indicator of the unobserved status of health or functioning) as
predictor of time-to-event. However, the literature on the latent class model
for survival data with a cure fraction is still sparse. Based on the subset of
the data published in D’Amico et al. (2002), we showed in Section 5 that
the proposed model with three latent cure rate markers fits the data best
based on LPML, DIC and the reversible jump of Green (1995). This finding
is consistent with the prostate cancer literature, as the three risk groups are
routinely used in the prostate cancer clinical practice.
18 S. KIM, Y. XI AND M.-H. CHEN
Although the proportional hazards (PH) assumption is assumed for the
cumulative hazard function H(y) for noncured subjects in (5), the result-
ing survival function is not PH due to the nature of the mixture model.
To examine the PH assumption, we first considered the generalized odds-
rate hazards (GORH) model discussed in Banerjee et al. (2007). We then
compared various GORH models for H(y) based on the LPML and DIC
measures to see whether a PH model for H(y) is appropriate. The results,
which are available in Kim, Xi and Chen (2009), empirically confirm that
the PH assumption for H(y) may be appropriate for the prostate cancer
data discussed in Section 1.
In Section 5, the covariates considered include only PSA, biopsy Gleason
score, clinical tumor category and year of RP due to the limitation of the
prostate cancer data we had. However, it will not add much additional com-
putational difficulty to incorporate more covariates into the proposed model.
Unlike D’Amico et al. (1998, 2002), the proposed model does not require
any prespecified cutoff values of the covariates in classifying patients into
different risk groups. The proposed method is potentially useful in clinical
applications as it allows doctors to include as many important covariates as
possible, some of which may be discovered later on due to medical advances,
for obtaining a more accurate risk classification.
In the LCRM model, we assume that there are G unknown latent θgi ’s.
Instead of the latent class model, we may assume a mixture of the Dirichlet
Process (MDP) model discussed in Ibrahim, Chen and Sinha (2001) for the
cure rate parameters. Specifically, we assign an unknown θi to each subject
and then assume a Dirichlet Process prior for θi. In Section 2.2, we assume
a piecewise exponential model for the baseline hazard function h0(y). One
possible extension to this is to assume a gamma process prior for h0(y),
which leads to a semiparametric LCRM model. These two extensions of the
LCRM model are currently under investigation.
APPENDIX: PROOFS OF THEOREMS
Proof of Theorem 1. After summing out N and g, we have
π(β,θ,φ,λ|Dobs)∝ π
∗(β,θ,φ,λ|Dobs )
= L(β,θ,φ,λ|Dobs)
×
[
J∏
j=1
λ−1j
][
G∏
k=1
θak−1k exp(−bkθk)
]
π(φ),
where L(β,θ,φ,λ|Dobs) is given by (10). It suffices to show that∫
π∗(β,θ,φ,λ|Dobs )dβ dθ dφdλ<∞.(A.1)
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It is easy to show that
L(β,θ,φ,λ|Dobs)
≤
∏
{i : νi=1}
θG exp
{
x′iβ+
J∑
j=1
δij logλj − exp(x
′
iβ)H
∗
0 (yi)
}
.
Using condition (iv), we can show
∫
θdG
[
G∏
k=1
θak−1k exp(−bkθk)
]
π(φ)dθ dφ<∞
due to the constraints, 0< θ1 < θ2 < · · ·< θG, and the condition, ak > 0 and
bk ≥ 0, for k = 1,2, . . . ,G− 1. Let
π∗(β,λ|Dobs ) =
[ ∏
{i:νi=1}
exp
{
x′iβ+
J∑
j=1
δij logλj − exp(x
′
iβ)H
∗
0 (yi)
}]
×
[
J∏
j=1
λ−1j
]
.
In order to establish (A.1), we only need to prove∫
π∗(β,λ|Dobs)dβ dλ<∞.(A.2)
Consider the transformation uj = log(λj), and let u = (u1, . . . , uJ)
′. Then,
dλj = λjduj , j = 1,2, . . . , J , and
π∗(β,u|Dobs ) = π
∗(β,λ|Dobs )
∣∣∣∣∂(λ1, λ2, . . . , λJ)∂(u1, u2, . . . , uJ)
∣∣∣∣
=
J∏
j=1
∏
{i : νi=1}
(
{exp(uj + x
′
iβ)}
δij
× exp
{
−δij exp(x
′
iβ)
×
[
exp(uj)(yi − sj−1)
+
j−1∑
l=1
exp(ul)(sl − sl−1)
]})
.
Letting δiji = 1 and δij = 0 for j 6= ji, we have
π∗(β,u|Dobs )≤ π
∗∗(β,u|Dobs)
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=
∏
{i : νi=1}
exp(uji + x
′
iβ) exp{−(yi − sji−1) exp(uji + x
′
iβ)},
and it suffices to show that
∫
π∗∗(β,u|Dobs)dβ du<∞. We rewrite π
∗∗(β,
u|Dobs ) as
π∗∗(β,u|Dobs)
=
J∏
j=1
∏
{i : νi=1,ji=j}
exp(uj + x
′
iβ) exp{−(yi − sj−1) exp(uj + x
′
iβ)}
=
∏
j 6=j∗
∏
{i : νi=1,ji=j}
exp(uj + x
′
iβ) exp{−(yi − sj−1) exp(uj + x
′
iβ)}
×
∏
{i : νi=1,ji=g∗}
exp(uj + x
′
iβ) exp{−(yi − sj−1) exp(uj + x
′
iβ)}.
Since dj ≥ 1, there exists sj−1 < yij ≤ sj for j 6= j
∗. Thus,∏
j 6=j∗
∏
{i : νi=1,ji=j}
exp(uj + x
′
iβ) exp{−(yi − sj−1) exp(uj + x
′
iβ)}
≤K1
∏
j 6=j∗
exp(uj + x
′
ij
β) exp{−(yij − sj−1) exp(uj + x
′
ij
β)},
where K1 > 0 is a constant, and∫ ∏
j 6=j∗
∏
{i : νi=1,ji=j}
exp(uj + x
′
iβ) exp{−(yi − sj−1) exp(uj + x
′
iβ)}
×
(∏
j 6=j∗
duj
)
≤K2
∏
j 6=j∗
∫ ∞
−∞
exp(uj + x
′
ij
β) exp{−(yij − sj−1) exp(uj + x
′
ij
β)}duj
=K2
∏
j 6=j∗
(yij − sj−1)
−1,
where K2 > 0 is a constant. For j = j
∗, without loss of generality, we as-
sume yi∗1 , . . . , yi
∗
p+1
∈ (sj∗−1, sj∗], and X
∗
j∗ , which has the lth row (1,x
′
i∗
l
),
ℓ= 1, . . . , p+1, is of full rank. Therefore,∏
{i : νi=1,ji=j∗}
exp(uj∗ + x
′
iβ) exp{−(yi − sj∗−1) exp(uj∗ + x
′
iβ)}
≤K3
p+1∏
l=1
exp{u∗j + x
′
i∗
l
β} exp{−(yi∗
l
− sj∗−1) exp(u
∗
j + x
′
i∗
l
β)},
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where K3 > 0 is a constant. Now consider the transformation w = (w1, . . . ,
wp+1)
′ ≡X∗g∗
(uj∗
β
)
, which is a one-to-one transformation. We have
∫
Rp+1
p+1∏
l=1
exp(uj∗ + x
′
il∗
β) exp{−(yi∗
l
− sj∗−1) exp(uj∗ + x
′
il∗
β)}duj∗ dβ
∝
∫
Rp+1
p+1∏
l=1
exp(wl) exp{−(yi∗
l
− sj∗−1) exp(wl)}dwl
=
p+1∏
l=1
(yi∗
l
− sj∗−1)
−1.
Therefore,
∫
Rp+J
π∗∗(β,u|Dobs)dβ du≤K
( ∏
j 6=g∗
(yij − sj−1)
−1
)(p+1∏
l=1
(yi∗
l
− sj∗−1)
−1
)
<∞,
where K > 0 is a constant. This completes the proof. 
Proof of Theorem 2. It is sufficient to show that P (gnew = k|β,θ,φ,
λ, t,xnew ,znew ,G) for k = 1 (k = G) increases (decreases) in t. We can
rewrite the conditional predictive probability in (18) as
P (gnew = k|β,θ,φ,λ, t,xnew ,znew ,G)
=
exp(z′newφk)∑G
l=1 exp(z
′
newφl) exp(−(θl − θk)[1− exp{− exp(x
′
newβ)H
∗
0 (t)}])
.
SinceH∗0 (t) is an increasing function of t, θl−θ1 > 0 for l > 1, and θl−θG < 0
for l < G. Thus, pˆ(k|t,xnew ,znew ,G) increases in t for k = 1 and decreases
in t for k =G. 
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SUPPLEMENTARY MATERIAL
Checking the proportional hazards assumption and computational de-
velopment (DOI: 10.1214/08-AOAS238SUPP; .pdf). In online supplemen-
tary material we provide the empirical results for checking the proportional
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hazards assumption and the description of the Markov chain Monte Carlo
(MCMC) sampling algorithm for a fixed G and the detailed development of
the reversible jump MCMC.
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